Use of cannabinoids in the treatment of epilepsy
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
1. A method of treating seizures associated with treatment-resistant Lennox-Gastaut syndrome or treatment-resistant Dravet syndrome in a patient in need thereof, comprising administering to the patient an oral solution comprising (i) a highly purified botanical drug substance (BDS), (ii) sesame oil, (iii) a sweetener, (iv) flavoring, and (v) ethanol,
wherein the BDS comprises at least 95% w/w cannabidiol (CBD), with the remainder comprising three or more of cannabidiolic acid (CBDA), cannabidivarin (CBDV), delta-9 tetrahydrocannabinol (Δ 9 THC), or cannabidiol-C4 (CBD-C4).
2. An oral solution comprising (i) a highly purified botanical drug substance (BDS), (ii) sesame oil, (iii) a sweetener, (iv) flavoring, and (v) ethanol,
wherein the highly purified BDS comprises at least 95% w/w cannabidiol (CBD), with the remainder comprising three or more of cannabidiolic acid (CBDA), cannabidivarin (CBDV), delta-9 tetrahydrocannabinol (Δ 9 THC), or cannabidiol-C4 (CBD-C4).
3. The oral solution of claim 2 , wherein the highly purified BDS comprises at least 95% w/w CBD, and the remainder comprises CBDV Δ 9 THC, and CBD-C4.
4. The oral solution of claim 3 , wherein CBDV is present in an amount of not more than 1.0% w/w.
5. The oral solution of claim 3 , wherein Δ 9 THC is present in an amount of not more than 0.15% w/w.
6. The oral solution of claim 3 , wherein CBD-C4 is present in an amount of not more than 0.5% w/w.
7. The oral solution of claim 3 , wherein:
CBDV is present in an amount of not more than 1.0% w/w;
Δ 9 THC is present in an amount of not more than 0.15% w/w; and
CBD-C4 is present in an amount of not more than 0.5% w/w.
8. The oral solution of claim 7 , wherein the sweetener is present at a concentration ranging from about 0.45 mg/mL, to about 0.55 mg/mL.
9. The oral solution of claim 7 , wherein flavoring is present at a concentration ranging from about 0.18 mg/mL to about 0.22 mg/mL.
10. The oral solution of claim 7 , wherein ethanol is present at a concentration ranging from about 71.1 mg/mL to about 86.9 mg/mL.
11. The oral solution of claim 7 , wherein:
the sweetener is present at a concentration ranging from about 0.45 mg/mL to about 0.55 mg/mL;
the flavoring is present at a concentration ranging from about 0.18 mg/mL to about 0.22 mg/mL; and
ethanol is present at a concentration ranging from about 71.1 mg/mL to about 86.9 mg/mL.
12. The oral solution of claim 11 , wherein the sweetener is sucralose.
13. The oral solution of claim 11 , wherein the flavoring is strawberry flavoring.
14. A highly purified botanical drug substance (BDS) comprising at least 95% w/w cannabidiol (CBD), with the remainder comprising three or more of cannabidiolic acid (CBDA), cannabidivarin (CBDV), delta-9 tetrahydrocannabinol (Δ 9 THC), or cannabidiol-C4 (CBD-C4).
15. The highly purified BDS of claim 14 , comprising not more than 0.15% w/w CBDA.
16. The highly purified BDS of claim 14 , comprising not more than 1.0% w/w CBDV.
17. The highly purified BDS of claim 14 , comprising not more than 0.15% w/w Δ 9 THC.
18. The highly purified BDS of claim 14 , comprising not more than 0.5% w/w CBD-C4.
19. The highly purified BDS of claim 14 , comprising CBDV, Δ 9 THC, and CBD-C4.
20. The highly purified BDS of claim 19 , wherein:
CBDV is present in an amount of not more than 1.0% w/w;
Δ 9 THC is present in an amount of not more than 0.15% w/w; and
CBD-C4 is present in an amount of not more than 0.5% w/w.
21. The oral solution of claim 2 , wherein:
the sweetener is present at a concentration ranging from about 0.45 mg/mL to about 0.55 mg/mL;
the flavoring is present at a concentration ranging from about 0.18 mg/mL to about 0.22 mg/mL; and
ethanol is present at a concentration ranging from about 71.1 mg/mL to about 86.9 mg/mL.
22. The oral solution of claim 21 , wherein the sweetener is sucralose.
23. The oral solution of claim 21 , wherein the flavoring is strawberry flavoring.
24. The oral solution of claim 2 , comprising from about 90 to about 110 mg/mL CBD.
25. The oral solution of claim 7 , comprising from about 90 to about 110 mg/mL CBD.
26. The oral solution of claim 11 , comprising from about 90 to about 110 mg/mL CBD.
27. An oral solution comprising (i) from about 90 to about 110 mg/mL CBD, (ii) sesame oil, (iii) a sweetener, (iv) flavoring, and (v) ethanol,
wherein the CBD is present in a highly purified BDS which comprises at least 95 w/w CBD, with the remainder comprising: not more than 1.0% w/w CBDV; not more than 0.15% w/w Δ 9 THC ; and not more than 0.5 w/w CBD-C4.
28. The oral solution of claim 25 , wherein:
the sweetener is present at a concentration ranging from about 0.45 mg/mL to about 0.55 mg/mL;
the flavoring is present at a concentration ranging from about 0.18 mg/mL to about 0.22 mg/mL; and
ethanol is present at a concentration ranging from about 71.1 mg/mL to about 86.9 mg/mL.
29. The oral solution of claim 28 , wherein the sweetener is sucralose.
30. The oral solution of claim 28 , wherein the flavoring is strawberry flavoring.
31. The method of claim 1 , wherein the CBD is administered to the patient in an amount ranging from about 5 mg/kg/day to about 25 mg/kg/day.
32. The method of claim 31 , wherein the amount of the CBD administered to the patient is about 10 mg/kg/day.
33. The method of claim 31 , wherein the amount of the CBD administered to the patient is about 20 mg/kg/day.